Establishment Labs (NASDAQ:ESTA - Free Report) had its target price raised by BTIG Research from $62.00 to $65.00 in a research report sent to investors on Monday morning, Benzinga reports. BTIG Research currently has a buy rating on the stock.
Other equities research analysts also recently issued reports about the company. Stephens restated an overweight rating and issued a $68.00 price target on shares of Establishment Labs in a report on Wednesday, August 7th. Citigroup increased their target price on Establishment Labs from $45.00 to $50.00 and gave the stock a neutral rating in a research note on Tuesday, October 1st. Finally, JPMorgan Chase & Co. cut their price target on shares of Establishment Labs from $61.00 to $50.00 and set an overweight rating on the stock in a research note on Wednesday, August 7th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of Moderate Buy and an average price target of $58.83.
View Our Latest Research Report on Establishment Labs
Establishment Labs Trading Up 3.6 %
Shares of ESTA stock traded up $1.45 on Monday, reaching $41.28. The company had a trading volume of 314,767 shares, compared to its average volume of 378,879. The company has a 50-day moving average of $42.46 and a 200-day moving average of $46.82. Establishment Labs has a 12 month low of $16.96 and a 12 month high of $60.12. The stock has a market cap of $1.14 billion, a PE ratio of -13.31 and a beta of 1.20. The company has a current ratio of 4.44, a quick ratio of 2.91 and a debt-to-equity ratio of 4.30.
Establishment Labs (NASDAQ:ESTA - Get Free Report) last posted its earnings results on Tuesday, August 6th. The company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.11). Establishment Labs had a negative return on equity of 220.67% and a negative net margin of 54.97%. The firm had revenue of $44.12 million during the quarter, compared to analyst estimates of $43.10 million. During the same quarter last year, the business posted ($0.65) earnings per share. The company's revenue for the quarter was down 9.2% on a year-over-year basis. On average, equities analysts forecast that Establishment Labs will post -2.27 earnings per share for the current year.
Institutional Trading of Establishment Labs
Institutional investors have recently made changes to their positions in the business. Capital Research Global Investors bought a new stake in Establishment Labs during the 1st quarter worth about $45,888,000. William Blair Investment Management LLC acquired a new position in Establishment Labs during the first quarter valued at approximately $21,415,000. First Turn Management LLC bought a new position in shares of Establishment Labs in the second quarter valued at $16,812,000. Sofinnova Investments Inc. increased its holdings in Establishment Labs by 204.1% during the second quarter. Sofinnova Investments Inc. now owns 429,244 shares of the company's stock worth $19,505,000 after buying an additional 288,082 shares during the last quarter. Finally, Divisadero Street Capital Management LP bought a new stake in Establishment Labs during the second quarter worth $5,829,000. Institutional investors own 72.91% of the company's stock.
About Establishment Labs
(
Get Free Report)
Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.
Recommended Stories
Before you consider Establishment Labs, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Establishment Labs wasn't on the list.
While Establishment Labs currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.